Shim Jaehee V, Xiong Yuguang, Dhanan Priyanka, Dariolli Rafael, Azeloglu Evren U, Hu Bin, Jayaraman Gomathi, Schaniel Christoph, Birtwistle Marc R, Iyengar Ravi, Dubois Nicole C, Sobie Eric A
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Institute for Systems Biomedicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Front Pharmacol. 2023 Apr 10;14:1158222. doi: 10.3389/fphar.2023.1158222. eCollection 2023.
Tyrosine kinase inhibitor drugs (TKIs) are highly effective cancer drugs, yet many TKIs are associated with various forms of cardiotoxicity. The mechanisms underlying these drug-induced adverse events remain poorly understood. We studied mechanisms of TKI-induced cardiotoxicity by integrating several complementary approaches, including comprehensive transcriptomics, mechanistic mathematical modeling, and physiological assays in cultured human cardiac myocytes. Induced pluripotent stem cells (iPSCs) from two healthy donors were differentiated into cardiac myocytes (iPSC-CMs), and cells were treated with a panel of 26 FDA-approved TKIs. Drug-induced changes in gene expression were quantified using mRNA-seq, changes in gene expression were integrated into a mechanistic mathematical model of electrophysiology and contraction, and simulation results were used to predict physiological outcomes. Experimental recordings of action potentials, intracellular calcium, and contraction in iPSC-CMs demonstrated that modeling predictions were accurate, with 81% of modeling predictions across the two cell lines confirmed experimentally. Surprisingly, simulations of how TKI-treated iPSC-CMs would respond to an additional arrhythmogenic insult, namely, hypokalemia, predicted dramatic differences between cell lines in how drugs affected arrhythmia susceptibility, and these predictions were confirmed experimentally. Computational analysis revealed that differences between cell lines in the upregulation or downregulation of particular ion channels could explain how TKI-treated cells responded differently to hypokalemia. Overall, the study identifies transcriptional mechanisms underlying cardiotoxicity caused by TKIs, and illustrates a novel approach for integrating transcriptomics with mechanistic mathematical models to generate experimentally testable, individual-specific predictions of adverse event risk.
酪氨酸激酶抑制剂药物(TKIs)是高效的抗癌药物,但许多TKIs与各种形式的心脏毒性有关。这些药物引起的不良事件背后的机制仍知之甚少。我们通过整合几种互补方法来研究TKI诱导的心脏毒性机制,包括全面的转录组学、机械数学建模以及在培养的人心肌细胞中的生理学测定。从两名健康供体获得的诱导多能干细胞(iPSCs)被分化为心肌细胞(iPSC-CMs),并用一组26种美国食品药品监督管理局(FDA)批准的TKIs处理细胞。使用mRNA测序对药物诱导的基因表达变化进行定量,将基因表达变化整合到电生理和收缩的机械数学模型中,并使用模拟结果预测生理结果。iPSC-CMs中动作电位、细胞内钙和收缩的实验记录表明,建模预测是准确的,两个细胞系中81%的建模预测在实验中得到证实。令人惊讶的是,对TKI处理的iPSC-CMs如何应对另一种致心律失常刺激(即低钾血症)的模拟预测了不同细胞系在药物影响心律失常易感性方面的巨大差异,并且这些预测在实验中得到了证实。计算分析表明,特定离子通道上调或下调的细胞系差异可以解释TKI处理的细胞对低钾血症的不同反应。总体而言,该研究确定了TKIs引起的心脏毒性的转录机制,并说明了一种将转录组学与机械数学模型相结合以生成可通过实验测试的、个体特异性不良事件风险预测的新方法。